Neuland Laboratories share price
You have to be logged in to add this to Watchlist.- ₹14,908.90(1.19%)April 10, 2026 15:29:58 PM IST
- NSE
- BSE
- Vol : 54.18 K (NSE + BSE)Last 20 day avg : 43.39 K
Neuland Laboratories is trading 1.19% upper at Rs 14,908.90 as compared to its last closing price. Neuland Laboratories has been trading in the price range of 15,091.35 & 14,650.00. Neuland Laboratories has given -1.48% in this year & 20.25% in the last 5 days. Neuland Laboratories has TTM P/E ratio 108.69 as compared to the sector P/E of 22.25.There are 4 analysts who have initiated coverage on Neuland Laboratories. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 40.57 Crores in its last quarter.Listed peers of Neuland Laboratories include Pfizer (2.53%), Aurobindo Pharma (0.86%), Jagsonpal Pharmaceuticals (-0.57%).The Mutual Fund holding in Neuland Laboratories was at 11.35% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Neuland Laboratories was at 20.46% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Apr 13, 2026, 02:42 AM UTC
- BetaMedium volatility0.85Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.10The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.08Annual dividends as a percentage of the stock price.
- PEG RatioIndicates Fair Valuation1.77The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Pfizer | Neutral | 4,868.60 | 2.53 | 22,223.60 | 36.12 | 0 | 0.69 | 1.60 |
| Aurobindo Pharma | Bullish | 1,351.00 | 0.86 | 78,489.74 | 20.15 | 0 | 0.33 | 5.52 |
| Jagsonpal Pharmaceuticals | Moderately Bullish | 192.55 | -0.57 | 1,288.69 | 33.88 | 5.54 | 1.25 | 3.18 |
| Themis Medicare | Neutral | 83.27 | 0.85 | 767.57 | 31.81 | 2.35 | 0.49 | 4.62 |
| Unichem Laboratories | Neutral | 341.95 | 2.12 | 2,385.09 | 23.18 | 1.29 | - | 3.51 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-02-09 | Quarterly Results |
| 2025-11-07 | Quarterly Results |
| 2025-07-31 | Quarterly Results |
| 2025-05-15 | Audited Results & Final Dividend |
| 2025-02-10 | Quarterly Results |
- IndustryMajor Drugs
- ISININE794A01010
- BSE Code524558
- NSE CodeNEULANDLAB
Neuland Laboratories is trading at 14908.90 as on Fri Apr 10 2026 09:59:58. This is 1.19% upper as compared to its previous closing price of 14733.50.
The market capitalization of Neuland Laboratories is 19109.15 Cr as on Fri Apr 10 2026 09:59:58.
The average broker rating on Neuland Laboratories is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Neuland Laboratories is 19748.40 whereas the 52 wk low is 10060.00
Neuland Laboratories can be analyzed on the following key metrics -
- TTM P/E: 108.69
- Sector P/E: 22.25
- Dividend Yield: 0.08%
- D/E ratio: -
Neuland Laboratories reported a net profit of 260.11 Cr in 2025.
The Mutual Fund Shareholding was 11.35% at the end of 31 Mar 2026.